Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26299055 | 0.97 | KMT2A (0.50) | KMT2APKMKDM4EPOLBATM | |
| SCHEMBL7515096 | 0.81 | KMT2A (0.46) | KMT2APKMKDM4EPOLBATM | |
| SCHEMBL7515740 | 0.80 | KMT2A (0.45) | KMT2APKMKDM4EPOLBATM | |
| SCHEMBL26299049 | 0.79 | PDE10A (0.42) | KMT2APKMKDM4EPOLBATM | |
| SCHEMBL7456708 | 0.78 | KMT2A (0.46) | KMT2APKMKDM4EATM | |
| SCHEMBL9106126 | 0.77 | POLB (0.49) | POLB | |
| SCHEMBL21960399 | 0.76 | MEN1 (0.56) | KMT2APKMKDM4EPOLBHPGD | |
| SCHEMBL14672263 | 0.76 | POLB (0.47) | POLBHPGD | |
| SCHEMBL2212203 | 0.74 | L3MBTL1 (0.39) | KMT2AKDM4EPOLBHPGDSMN1; SMN2 | |
| SCHEMBL26299072 | 0.74 | KMT2A (0.37) | KMT2APKMSMN1; SMN2MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | NFKBIA, IKBKG, IKBKE | KMT2A 1706/4885PKM 1366/4885KDM4E 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.